戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 level was determined by identifying the most emetogenic agent in the combination and then assessing t
2 mbination by one level greater than the most emetogenic agent in the combination; and (3) adding leve
3 titration of sedatives, en route to avoiding emetogenic and hyperalgesic volatile anesthetics.
4 ross multiple cycles of moderately or highly emetogenic chemotherapies.
5 heduled to receive the first cycle of highly emetogenic chemotherapy (HEC).
6 nagement problem after treatment with highly emetogenic chemotherapy (HEC).
7 ea and vomiting in patients receiving highly emetogenic chemotherapy (HEC).
8                Patients receiving moderately emetogenic chemotherapy (MEC) are commonly prescribed a
9  not been adequately evaluated in moderately emetogenic chemotherapy (MEC) regimens with or without n
10 ind, parallel-group study, patients naive to emetogenic chemotherapy (N = 1,085) who were scheduled t
11 r, who had not received moderately or highly emetogenic chemotherapy before, with a Karnofsky perform
12 ptor, about 50% of patients given moderately emetogenic chemotherapy have delayed nausea.
13 omiting associated with moderately or highly emetogenic chemotherapy in adults, but its efficacy and
14                                       Highly emetogenic chemotherapy induces emesis in almost all pat
15 sk period after administration of moderately emetogenic chemotherapy or regimens containing an anthra
16 th cancer after administration of moderately emetogenic chemotherapy or regimens containing an anthra
17              All patients who receive highly emetogenic chemotherapy regimens (including anthracyclin
18 ecutive administrations of moderately/highly emetogenic chemotherapy were assessed for errors.
19 duled to receive either moderately or highly emetogenic chemotherapy were randomly assigned with an i
20 7% of participants given moderate and highly emetogenic chemotherapy, respectively.
21 inical trials with patients receiving highly emetogenic chemotherapy, the neurokinin antagonist aprep
22 ents receiving taxanes as part of moderately emetogenic chemotherapy, who received dexamethasone acco
23 ter administration of cisplatin-based highly emetogenic chemotherapy.
24  about 1-2 h before administration of highly emetogenic chemotherapy.
25  corticosteroid in patients receiving highly emetogenic chemotherapy.
26 ents being treated with moderately or highly emetogenic chemotherapy.
27 erapy-naive patients who received moderately emetogenic chemotherapy.
28 ea and vomiting in patients receiving highly emetogenic chemotherapy.
29 untreated patients who were receiving highly emetogenic chemotherapy.
30 25-120 h (delayed phase) after initiation of emetogenic chemotherapy.
31 p) 1-2 h before administration of moderately emetogenic chemotherapy.
32 on against CINV in patients receiving highly emetogenic cisplatin-based chemotherapy.
33 eriod (120 h) after administration of highly emetogenic cisplatin-based chemotherapy.
34 tron (32 mg) in patients who received highly emetogenic, cisplatin-based chemotherapy.
35  and/or vomiting during moderately or highly emetogenic, intravenous chemotherapy despite guideline-c
36  (1) level 1 agents do not contribute to the emetogenic level of a combination; (2) adding > or = one
37                        For combinations, the emetogenic level was determined by identifying the most
38  assigned chemotherapy agents to one of five emetogenic levels by consensus.
39 s were challenged intraperitoneally with the emetogenic NK agonist GR73632 at different doses, and vo
40  provides a practical means to determine the emetogenic potential of individual chemotherapy agents a